Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology/Oncology Fellowship, University of North Carolina, Chapel Hill, School of Medicine 1998 - 2001
  • Internal Medicine Residency, University of Michigan, Ann Arbor 1995 - 1998
  • M.D., University of Virginia School of Medicine 1995
• 

  Previous Appointments & Affiliations

  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2016 - 2017
• Research
• 

  Selected Grants

  • Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 awarded by Nuvalent, Inc. 2023 - 2027
  • A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors awarded by Rain Therapeutics, Inc. 2022 - 2027
  • This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 Tumor Proportion Score. awarded by Mirati Therapeutics, Inc. 2021 - 2026
  • Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations awarded by Seattle Genetics, Inc 2020 - 2025
  • Single arm phase 2 trial of atezolizumab and bevacizumab in Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lu¬¬ng cancer in patients with disease progression after osimertinib" awarded by Genentech, Inc. 2020 - 2025
  • Dialectical Behavioral Therapy Skills Training for Metastatic Lung Cancer Patients awarded by National Institutes of Health 2021 - 2024
  • A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer awarded by Dana-Farber Cancer Institute 2018 - 2024
  • A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer awarded by Advaxis Inc 2019 - 2023
  • Empower treatment effects evaluation of randomized clinical trials for elderly patients with integrated real-world data awarded by North Carolina State University 2020 - 2023
  • A Single Arm Phase II Study Osimertinib in Patients with Stage 4 Non-small Cell Lung Cancer with Uncommon EGFR Mutations Thoracic Oncology Program (TOP) Protocol Number: TOP 1703 awarded by AstraZeneca LP 2018 - 2023
  • Phase 2 Trial of Brigatinib after Treatment with Second-Generation ALK inhibitors in Refractory ALK Rearranged NSCLC awarded by Millennium Pharmaceuticals, Inc. 2017 - 2022
  • A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer awarded by Merck 2017 - 2022
  • Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2016 - 2021
  • Mechanisms of immune checkpoint resistance mediated by LKB1 tumor suppressor in lung cancer awarded by Department of Defense 2019 - 2021
  • A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER awarded by Regeneron Pharmaceuticals, Inc. 2020
  • A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer awarded by TESARO 2018 - 2020
  • A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors awarded by Blueprint Medicines Corporation 2017 - 2020
  • A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of embrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squam awarded by Novartis Pharmaceuticals Corporation 2019 - 2020
  • Safety, Activity, and Pharmacology of Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease awarded by Alliance Foundation Trials, LLC 2019 - 2020
  • A Phase 1b/2, single-arm, open-label, multi-center study of MP0250 in combination with osimertinib in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) pretreated with osimertinib awarded by Molecular Partners AG 2018 - 2020
  • A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer awarded by Alliance Foundation Trials, LLC 2017 - 2018
  • A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER awarded by Pfizer, Inc. 2017 - 2018
• 

  External Relationships

  • AstraZeneca
  • Daiichi Sankyo Co., Ltd
  • Eisai
  • G1 Therapeutics, Inc.
  • GSK
  • Genzyme Corporation (Sanofi Aventis)
  • Janssen Oncology
  • Roche/Genentech
  • Spectrum Pharmaceuticals
  • Takeda Oncology
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Kozono, David E., Thomas E. Stinchcombe, Joseph K. Salama, Jeffrey Bogart, W Jeffrey Petty, Michael J. Guarino, Lyudmila Bazhenova, et al. “Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.” Lung Cancer 159 (September 2021): 56–65. https://doi.org/10.1016/j.lungcan.2021.06.028.
       Full Text  Link to Item
    • Weiss, Jared, Brian Kavanagh, Allison Deal, Liza Villaruz, James Stevenson, Ross Camidge, Hossein Borghaei, et al. “Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.” Cancer Treat Res Commun 19 (2019): 100126. https://doi.org/10.1016/j.ctarc.2019.100126.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.